Home > Insights > Eviscerating patent law?
30 September, 2014

Matthew Spencer, Partner at Boult Wade Tennant, offers his opinion on the recent guidance from the US Patent and Trademark Office for subject matter eligibility analysis. In an article appearing in Nature’s BioPharma Dealmakers, Matthew questions whether the guidance given threatens to stifle investment and innovation.

Read the article or visit the site.


Matthew Spencer Partner

Matthew Spencer

Phone this number +44 (0)1223 883000

Email this address mspencer@boult.com

CPC4 Capital Park
Cambridge Road
CB21 5XE